Table 1 Summary statistics for patient characteristics in the CRASH-2 trial
From: Including random centre effects in design, analysis and presentation of multi-centre trials
Patient level characteristics | Tranexamic acid (n = 10,060) | Placebo (n = 10,067) |
|---|---|---|
Age (years) | ||
Mean (SD) | 34.6 (14.14) | 34.5 (14.39) |
< 25 | 2777 (27.6%) | 2838 (28.2%) |
25–34 | 3006 (29.9%) | 3070 (30.5%) |
35–44 | 1966 (19.5%) | 1832 (18.2%) |
> 44 | 2311 (23.0%) | 2326 (23.1%) |
Sex | ||
Men | 8413 (83.6%) | 8456 (84.0%) |
Women | 1647 (16.4%) | 1610 (15.99%) |
Not known | 0 | 1 (0.01%) |
Glasgow Coma Scale (total) | ||
Severe (3–8) | 1789 (17.8%) | 1830 (18.2%) |
Moderate (9–12) | 1349 (13.4%) | 1344 (13.4%) |
Mild (13–15) | 6915 (68.7%) | 6877 (68.3%) |
Not known | 7 (< 1%) | 16 (< 1%) |
Time since injury (hours) | ||
Mean (SD) | 3.22 (19.99) | 3.26 (20.03) |
≤ 1 | 3747 (37.3%) | 3705 (36.8%) |
> 1–3 | 3037 (30.2%) | 2996 (29.8%) |
> 3 | 3272 (32.5%) | 3362 (33.4%) |
Not known | 4 (0.04%) | 4 (0.04%) |
Type of injury | ||
Blunt* | 6788 (67.5%) | 6817 (67.7%) |
Penetrating | 3272 (32.5%) | 3250 (32.3%) |
Systolic blood pressure (mm Hg) | ||
≤ 75 | 1562 (15.5%) | 1599 (15.9%) |
76–89 | 1609 (16.0%) | 1689 (16.8%) |
≥ 90 | 6878 (68.4%) | 6761 (67.2%) |
Not known | 11 (< 1%) | 18 (< 1%) |
28-day mortality | ||
Dead (all-cause) | 1463 (14.5%) | 1613 (16.0%) |
Dead due to bleeding | 489 (4.9%) | 575 (5.7%) |